A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL)

• Status: Completed
• Trial end date: 2011-04-01

Summary

This is an open-label study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine to assess this 5-drug treatment's safety and tolerability in pediatric patients with first relapse Acute Lymphoblastic Leukemia (ALL).

• Phase: Phase 1

Details

• Lead Sponsor: Genzyme, a Sanofi Company
• Treatments: Asparaginase; Clofarabine; Cyclophosphamide; Etoposide; Etoposide phosphate; Pegaspargase; Vincristine